Health And Pharma
WEBHealth & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
The LUMINOSITY Trial: Exploring c-Met and SEZ6 Targets in the …
WEB1 day ago · Antibody-drug conjugates (ADCs) represent a significant breakthrough in oncology, offering targeted treatments, especially for lung cancer. In this exclusive interview, we speak with Professor Nicolas Girard, Head of the Curie-Montsouris Thorax Institute at Institut Curie and Professor of Respiratory Medicine at Versailles Saint Quentin University, to explore the latest advancements in ADC ...
Bayer's New Lung Cancer Drug Receives Critical FDA Breakthrough …
WEB1 March 2024. Bayer announced that its investigational drug BAY 2927088 has been awarded the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). This promising development brings new hope to patients battling non-small cell lung cancer (NSCLC) with specific HER2 activating mutations, offering a potential new avenue ...
ONCOLife | Health And Medicine
WEBONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is dedicated to covering key developments in the field of oncology. We delve into the stories behind significant clinical research and drug developments ...
A New Era in Oncology: Programmable mRNA Therapies in the …
WEBApr 4, 2024 · Strand Therapeutics promises a new class of cancer treatment with its programmable mRNA therapies designed to precisely target cancer cells. With FDA clearance for a Phase 1 trial of their lead therapy, STX-001, they aim to improve solid tumor treatment outcomes and advance personalized medicine. Strand Therapeutics, an enterprise born from the ...
Boehringer Ingelheim's P-II Trial Sparks Hope for Chronic Kidney ...
WEB4 November 2023. A groundbreaking Phase II trial by Boehringer Ingelheim shows its novel aldosterone synthase inhibitor BI 690517, on top of empagliflozin, significantly reduces albuminuria in CKD patients by up to 39.5%. The results of the trial, presented at the American Society of Nephrology's Kidney Week 2023, promise a new treatment ...
Targeting Hard-to-Treat Cancers: The Potential of Antibody-Drug …
WEB4 days ago · 4 October 2024. Antibody-drug conjugates (ADCs) are transforming the landscape of cancer treatment by targeting hard-to-treat cancers with precision. We will have an interview with Dr. Paul Moore, Chief Scientific Officer of Zymeworks, where we discuss their innovative ADC and its potential to address unmet medical needs in …
Gilead and Merck Announce Historic Data for HIV Treatment: A …
WEBMar 8, 2024 · “HIV treatment is not one size fits all – developing once-weekly treatment options could help meet the needs of each individual, aiming toward maximizing long-term outcomes for people with HIV,” said Dr. Jared Baeten, Vice President, HIV Clinical Development, Gilead Sciences. “These promising data presented at CROI help bring us one step closer to our goal of providing a wide range of ...
Healthy Planet: How The Pharmaceutical Industry Can Reduce Its …
WEBAug 9, 2024 · A potential net increase of 529,000 adult deaths worldwide per year by 2050 due to climate change has been predicted, and even though the global pharmaceutical industry is in the business of keeping people healthy, it is also responsible for approximately 52 megatons of carbon dioxide equivalent emissions annually.. This equates to roughly 4.5 percent of total greenhouse gas emissions and ...
MicroRNA-Based Gene Therapy, Holds Promise in Battle Against …
WEBAug 26, 2023 · Researchers from the UC Davis Comprehensive Cancer Center have identified microRNA-22 (miR-22) as a promising new treatment for hepatocellular carcinoma, the most prevalent type of liver cancer.